Alnylam Pharmaceuticals, INC. DEFA14A Filing
Ticker: ALNY · Form: DEFA14A · Filed: Apr 6, 2026 · CIK: 0001178670
Sentiment: neutral
Filing Stats: 127 words · 1 min read · ~1 pages · Grade level 12.3 · Accepted 2026-04-06 16:31:25
Filing Documents
- alny2026proxydefa14a.htm (DEFA14A) — 9KB
- alny2026proxydefa14asupporb.jpg (GRAPHIC) — 63KB
- alny2026proxydefa14asupporc.jpg (GRAPHIC) — 511KB
- image_0a.jpg (GRAPHIC) — 33KB
- 0001628280-26-023924.txt ( ) — 846KB
From the Filing
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to 240.14a-12 Alnylam Pharmaceuticals, Inc. (Name of Registrant as Specified in Its Charter) (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (Check all boxes that apply) No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.